{"brief_title": "Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis", "brief_summary": "The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.", "condition": "Aspergillosis", "intervention_type": "Drug", "intervention_name": "Liposomal Amphotericin B", "description": "IV", "arm_group_label": "1", "other_name": "AmBisome", "criteria": "Inclusion Criteria - Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy Exclusion Criteria - Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal - Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion - Has life expectancy of less than five days", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00047827.xml"}